Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
2.0 Credits / Ophthalmology/Optometry
View More
The Pharmacist’s Impact on Shingles Prevention Through Vaccination: Recommendations, Uptake, and Improved Outc...
1.5 Credits / Immunization
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: ...
1.0 Credit / Hematologic Cancer
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and...
1.0 Credit / Hematologic Cancer
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Pract...
1.0 Credit / Hematologic Cancer, Oncology
View More
Elevated Non-HDL Cholesterol a Stronger Indicator of Major Cardiovascular Events Compared With LDL-C
March 21st 2025Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.
Experts: Vast Disparities in Opioid Prescribing Observed for Minority Communities in Past Decade
March 21st 2025Allison Ju-Chen Hu, PhD and Yuhua Bao, PhD describe results of their landmark study that found significant differences in opioid prescriptions in racially and ethnically minoritized communities.
Guselkumab Receives FDA Approval for Adults With Moderately to Severely Active Crohn Disease
March 21st 2025The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.
Allo-SCT, Myeloablative Conditioning With Busulfan/Fludarabine Improves Survival in Myelofibrosis
March 20th 2025Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.